Similar articles for PMID: 16815316

Year	Number of Results
1996	2
1998	2
1999	4
2000	3
2001	8
2002	7
2003	17
2004	11
2005	23
2006	18
2007	20
2008	15
2009	9
2010	19
2011	6
2012	3
2013	5
2014	13
2015	9
2016	11
2017	6
2018	5
2019	9
2020	4
2021	10
2022	6
2023	1
2024	0

1

Influences of proinflammatory and anti-inflammatory cytokine polymorphisms on eradication rates of clarithromycin-sensitive strains of Helicobacter pylori by triple therapy.

Sugimoto M, Furuta T, Shirai N, Ikuma M, Hishida A, Ishizaki T. Sugimoto M, et al. Clin Pharmacol Ther. 2006 Jul;80(1):41-50. doi: 10.1016/j.clpt.2006.03.007. Epub 2006 Jun 8. Clin Pharmacol Ther. 2006. PMID: 16815316 Clinical Trial.

2

Effect of genotypic differences in CYP2C19 on cure rates for Helicobacter pylori infection by triple therapy with a proton pump inhibitor, amoxicillin, and clarithromycin.

Furuta T, Shirai N, Takashima M, Xiao F, Hanai H, Sugimura H, Ohashi K, Ishizaki T, Kaneko E. Furuta T, et al. Clin Pharmacol Ther. 2001 Mar;69(3):158-68. doi: 10.1067/mcp.2001.113959. Clin Pharmacol Ther. 2001. PMID: 11240980 Clinical Trial.

3

Polymorphism of interleukin-1beta affects the eradication rates of Helicobacter pylori by triple therapy.

Furuta T, Shirai N, Xiao F, El-Omar EM, Rabkin CS, Sugimura H, Ishizaki T, Ohashi K. Furuta T, et al. Clin Gastroenterol Hepatol. 2004 Jan;2(1):22-30. doi: 10.1016/s1542-3565(03)00288-x. Clin Gastroenterol Hepatol. 2004. PMID: 15017629 Clinical Trial.

4

Interleukin-1beta genetic polymorphism influences the effect of cytochrome P 2C19 genotype on the cure rate of 1-week triple therapy for Helicobacter pylori infection.

Take S, Mizuno M, Ishiki K, Nagahara Y, Yoshida T, Inaba T, Yamamoto K, Okada H, Yokota K, Oguma K, Shiratori Y. Take S, et al. Am J Gastroenterol. 2003 Nov;98(11):2403-8. doi: 10.1111/j.1572-0241.2003.07707.x. Am J Gastroenterol. 2003. PMID: 14638340 Clinical Trial.

5

Efficacy of triple therapy with rabeprazole for Helicobacter pylori infection in relation to CYP2C19 genotype.

Lee SB, Park SJ, Ryu JK, Lee JK, Kim HJ, Bae JS, Jung HS, Park SM. Lee SB, et al. Korean J Gastroenterol. 2003 Dec;42(6):468-75. Korean J Gastroenterol. 2003. PMID: 14695703

6

Impact of clarithromycin resistance and CYP2C19 genetic polymorphism on treatment efficacy of Helicobacter pylori infection with lansoprazole- or rabeprazole-based triple therapy in Japan.

Miki I, Aoyama N, Sakai T, Shirasaka D, Wambura CM, Maekawa S, Kuroda K, Tamura T, Kita T, Sakaeda T, Okumura K, Kasuga M. Miki I, et al. Eur J Gastroenterol Hepatol. 2003 Jan;15(1):27-33. doi: 10.1097/00042737-200301000-00006. Eur J Gastroenterol Hepatol. 2003. PMID: 12544691 Clinical Trial.

7

[Effect of CYP2C19 genetic polymorphism on treatment efficacy of Helicobacter pylori infection with rabeprazole-based triple therapy in Chinese].

He XX, Zhao YH, Hao YT. He XX, et al. Zhonghua Nei Ke Za Zhi. 2004 Jan;43(1):13-5. Zhonghua Nei Ke Za Zhi. 2004. PMID: 14990013 Clinical Trial. Chinese.

8

High-dose rabeprazole/amoxicillin therapy as the second-line regimen after failure to eradicate H. pylori by triple therapy with the usual doses of a proton pump inhibitor, clarithromycin and amoxicillin.

Furuta T, Shirai N, Xiao F, Takashita M, Sugimoto M, Kajimura M, Ohashi K, Ishizaki T. Furuta T, et al. Hepatogastroenterology. 2003 Nov-Dec;50(54):2274-8. Hepatogastroenterology. 2003. PMID: 14696516 Clinical Trial.

9

Efficacy of triple therapy with rabeprazole for Helicobacter pylori infection and CYP2C19 genetic polymorphism.

Hokari K, Sugiyama T, Kato M, Saito M, Miyagishima T, Kudo M, Nishikawa K, Ishizuka J, Komatsu Y, Mizushima T, Kagaya H, Hige S, Takeda H, Asaka M. Hokari K, et al. Aliment Pharmacol Ther. 2001 Sep;15(9):1479-84. doi: 10.1046/j.1365-2036.2001.01063.x. Aliment Pharmacol Ther. 2001. PMID: 11552922 Free article. Clinical Trial.

10

Effect of MDR1 C3435T polymorphism on cure rates of Helicobacter pylori infection by triple therapy with lansoprazole, amoxicillin and clarithromycin in relation to CYP 2C19 genotypes and 23S rRNA genotypes of H. pylori.

Furuta T, Sugimoto M, Shirai N, Matsushita F, Nakajima H, Kumagai J, Senoo K, Kodaira C, Nishino M, Yamade M, Ikuma M, Watanabe H, Umemura K, Ishizaki T, Hishida A. Furuta T, et al. Aliment Pharmacol Ther. 2007 Sep 1;26(5):693-703. doi: 10.1111/j.1365-2036.2007.03408.x. Aliment Pharmacol Ther. 2007. PMID: 17697203 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

231 results

Results by year